NRx Pharmaceuticals, Inc.
NASDAQ:NRXPBiotechnology
+$0.06 today
- Market cap
- $124.12M
- Beta
- 2.19
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$0.76
Volume 2.09M
Average 1.27M
NRXP Total Non-current Assets
All assets not expected to be converted to cash within one year.
NRx Pharmaceuticals, Inc.NASDAQ: NRXP
Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Total non-current assets rises 1259.9% from a year ago
Total non-current assets stood at $4.54M at the end of Q1 FY2026, up 1259.9% from a year earlier and up 11.8% from the prior quarter. Over 3 fiscal years it compounded at +478.4% a year.
Context
- Total non-current assets amounted to 38.2% of total assets at the end of Q1 FY2026, up 33.8 pp from a year earlier.
- Total non-current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current assets keeps rising in the next quarterly balance sheet after a +1259.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 4.06M USD
- Year-over-year change
- +1064.5%
- 4-year CAGR
- +305.7%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.06M | +1064.5% |
| FY2024 | 2024-12-31 | 349K | -19.0% |
| FY2023 | 2023-12-31 | 431K | +1952.4% |
| FY2022 | 2022-12-31 | 21K | +40.0% |
| FY2021 | 2021-12-31 | 15K | — |
Total Non-current Assets vs competitors
How NRXP compares with its peers on the latest reported figures
- NRXP's Mar 2026 total non-current assets of $4.54M is the 4th highest of the 9 companies compared; the peer median is $2.87M.
- Its year-over-year change of +1259.9% is the highest of 9, against a peer median of -8.2%.
- Total non-current assets amounts to 38.2% of total assets for NRXP, versus a peer median of 4.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $187.51M | +28.5% | -14.9% | 57.4% | |
| Mar 2026 | $13.88M | +57.7% | +46.5% | 70.1% | |
| Mar 2026 | $5.08M | -32.0% | -13.0% | 3.9% | |
| Mar 2026 | $4.54M | +1259.9% | +478.4% | 38.2% | |
| Mar 2026 | $4.49M | -29.1% | -28.1% | 14.5% | |
| Jun 2026 | $1.26M | -89.6% | -18.6% | 5.2% | |
| Mar 2026 | $1.13M | +5.7% | -23.6% | 2.0% | |
| Mar 2026 | $987.7K | -22.1% | +5.9% | 4.5% | |
| Mar 2026 | $808K | +57.5% | -26.9% | 1.3% | |
| Peer median (excluding NRXP) | $2.87M | -8.2% | -16.7% | 4.9% | |
Competitors are the stored peer set for NRXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
Intrinsic Alpha fair value
Locked
Current Price
$2.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.